POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
24 févr. 2021 08h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-Market
23 févr. 2021 17h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $17.6 Million Private Placement Priced At-the-Market
18 févr. 2021 09h00 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
17 févr. 2021 08h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
16 févr. 2021 17h00 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $7.4 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
11 févr. 2021 00h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer
08 févr. 2021 08h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
02 févr. 2021 12h00 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Litchfield Hills Research Rates Predictive Oncology a Buy on Recent Analyst Report
02 févr. 2021 08h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Soluble Biotech, a Wholly Owned Subsidiary of Predictive Oncology, Inked Contract with Large Pharmaceutical Company
28 janv. 2021 08h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...